These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 9074522)

  • 1. Sequential biological dosimetry after a single treatment with iodine-131 for differentiated thyroid carcinoma.
    M'Kacher R; Légal JD; Schlumberger M; Aubert B; Beron-Gaillard N; Gaussen A; Parmentier C
    J Nucl Med; 1997 Mar; 38(3):377-80. PubMed ID: 9074522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological dosimetry in patients treated with iodine-131 for differentiated thyroid carcinoma.
    M'Kacher R; Legal JD; Schlumberger M; Voisin P; Aubert B; Gaillard N; Parmentier C
    J Nucl Med; 1996 Nov; 37(11):1860-4. PubMed ID: 8917193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologic dosimetry in thyroid cancer patients after repeated treatments with iodine-131.
    M'Kacher R; Schlumberger M; Légal JD; Violot D; Béron-Gaillard N; Gaussen A; Parmentier C
    J Nucl Med; 1998 May; 39(5):825-9. PubMed ID: 9591584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiotoxicity after iodine-131 therapy for thyroid cancer using the micronucleus assay.
    Watanabe N; Yokoyama K; Kinuya S; Shuke N; Shimizu M; Futatsuya R; Michigishi T; Tonami N; Seto H; Goodwin DA
    J Nucl Med; 1998 Mar; 39(3):436-40. PubMed ID: 9529288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cytogenetic study of thyroid patients treated with external irradiation or radioiodine].
    Katz N; Esik O; Füzy M; Gundy S
    Orv Hetil; 1998 Jun; 139(25):1521-6. PubMed ID: 9676113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dosimetry and risk estimates of radioiodine therapy for large, multinodular goiters.
    Huysmans DA; Buijs WC; van de Ven MT; van den Broek WJ; Kloppenborg PW; Hermus AR; Corstens FH
    J Nucl Med; 1996 Dec; 37(12):2072-9. PubMed ID: 8970537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach.
    Dorn R; Kopp J; Vogt H; Heidenreich P; Carroll RG; Gulec SA
    J Nucl Med; 2003 Mar; 44(3):451-6. PubMed ID: 12621014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 131I Biokinetics and cytogenetic dose estimates in ablation treatment of thyroid carcinoma.
    Nascimento AC; Lipsztein JL; Corbo R; Rebelo AM
    Health Phys; 2010 Oct; 99(4):457-63. PubMed ID: 20838086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iodine-131 in breast milk following therapy for thyroid carcinoma.
    Robinson PS; Barker P; Campbell A; Henson P; Surveyor I; Young PR
    J Nucl Med; 1994 Nov; 35(11):1797-801. PubMed ID: 7965159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of short-term chromosomal damage due to therapeutic 131I exposure in patients with thyroid cancer.
    Hernández-Jardines A; Molina B; del Castillo V; Papadakis M; Rivera T; Azorín J; Herrera LA; Yokoyama E; Frías S
    Rev Invest Clin; 2010; 62(1):31-8. PubMed ID: 20415057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiated thyroid carcinoma in children and adolescents: a 37-year experience in 85 patients.
    Dottorini ME; Vignati A; Mazzucchelli L; Lomuscio G; Colombo L
    J Nucl Med; 1997 May; 38(5):669-75. PubMed ID: 9170425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute toxicity of adjuvant radiotherapy in locally advanced differentiated thyroid carcinoma. First results of the multicenter study differentiated thyroid carcinoma (MSDS).
    Schuck A; Biermann M; Pixberg MK; Müller SB; Heinecke A; Schober O; Willich N
    Strahlenther Onkol; 2003 Dec; 179(12):832-9. PubMed ID: 14652672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological dosimetry and Bayesian analysis of chromosomal damage in thyroid cancer patients.
    Serna A; Alcaraz M; Navarro JL; Acevedo C; Vicente V; Canteras M
    Radiat Prot Dosimetry; 2008; 129(4):372-80. PubMed ID: 17951242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
    DeNardo GL; DeNardo SJ; Shen S; DeNardo DA; Mirick GR; Macey DJ; Lamborn KR
    J Nucl Med; 1999 Aug; 40(8):1317-26. PubMed ID: 10450684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant external-beam radiotherapy in patients with high-risk well-differentiated thyroid cancer.
    Chen PV; Osborne R; Ahn E; Avitia S; Juillard G
    Ear Nose Throat J; 2009 Jul; 88(7):E01. PubMed ID: 19623515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer.
    Tuttle RM; Leboeuf R; Robbins RJ; Qualey R; Pentlow K; Larson SM; Chan CY
    J Nucl Med; 2006 Oct; 47(10):1587-91. PubMed ID: 17015892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer.
    Jentzen W; Freudenberg L; Eising EG; Sonnenschein W; Knust J; Bockisch A
    J Nucl Med; 2008 Jun; 49(6):1017-23. PubMed ID: 18483099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic administration of 131I for differentiated thyroid cancer: radiation dose to ovaries and outcome of pregnancies.
    Garsi JP; Schlumberger M; Rubino C; Ricard M; Labbé M; Ceccarelli C; Schvartz C; Henri-Amar M; Bardet S; de Vathaire F
    J Nucl Med; 2008 May; 49(5):845-52. PubMed ID: 18413399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR.
    Juweid ME; Hajjar G; Stein R; Sharkey RM; Herskovic T; Swayne LC; Suleiman S; Pereira M; Rubin AD; Goldenberg DM
    J Nucl Med; 2000 Jan; 41(1):93-103. PubMed ID: 10647610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-therapeutic blood dosimetry in patients with differentiated thyroid carcinoma using 124-iodine: predicted blood doses correlate with changes in blood cell counts after radioiodine therapy and depend on modes of TSH stimulation and number of preceding radioiodine therapies.
    Hartung-Knemeyer V; Nagarajah J; Jentzen W; Ruhlmann M; Freudenberg LS; Stahl AR; Bockisch A; Rosenbaum-Krumme SJ
    Ann Nucl Med; 2012 Nov; 26(9):723-9. PubMed ID: 22802008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.